서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 15 of 15

Issue DateTitle / Author(s) / CitationFileAltmetrics
2013-03
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
DOI
2017-12
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies
DOI
2018-03
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
DOI
2018-07
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
DOI
2018-09
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies
DOI
2019-01
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
DOI
2019-05
Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study
DOI
2019-07
Overall survival with ribociclib plus endocrine therapy in breast cancer
DOI
2019-10
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2020-01
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
DOI
2020-03
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2023-05
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer
DOI
2023-08
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
DOI
1